The Food and Drug Administration (FDA) has granted accelerated approval to Avmapki ™ (avutometinib) plus Fakzynja ™ (defactinib) for the treatment of adult patients with KRAS -mutated recurrent ...

The FDA granted accelerated approval to the combination of avutometinib and defactinib (Avmapki Fakzynja Co-pack) for the treatment of adults with KRAS -mutated, recurrent low-grade serous ovarian ...

The agency approved the treatment based on data from 57 patients with previously treated KRAS-mutant recurrent low-grade serous ovarian cancer.

The firm will test LP-184 as a monotherapy and in combination with a PARP inhibitor in patients who have DNA damage repair gene mutations.

The U.S. Food and Drug Administration has approved Verastem's combination therapy for patients with a rare type of ovarian ...

The FDA has granted accelerated approval to avutometinib (VS-6766) plus defactinib (VS-6063) for the treatment of adult ...

A woman's chances of surviving ovarian cancer at least five years after diagnosis come down to the toss of a coin: just 49% ...

A promising target for rare liver cancer, a functional cure for multiple myeloma — and support for people with ovarian cancer.

Polycystic ovarian syndrome (PCOS) is a complex disorder of metabolism, endocrine function, and the reproductive system that ...

DB-1305/BNT325 was generally well tolerated and exhibited “very encouraging and durable antitumor activity in ovarian cancer patients,” said Maria Rubinstein, MD.

The Company expects to submit a New Drug Application to the Food and Drug Administration in the third quarter of 2025.

The FDA has granted fast track designation to INX-315 for the treatment of CCNE1-amplified, platinum-resistant/refractory ovarian cancer.